Mineralcorticoid receptor blockers in chronic kidney disease
There are many experimental data supporting the involvement of aldosterone and mineralcorticoid receptor (MR) activation in the genesis and progression of chronic kidney disease (CKD) and cardiovascular damage.Many studies have shown that in diabetic and non-diabetic CKD, blocking the renin-angioten...
Main Authors: | Sara Erraez, Manuel López-Mesa, Pablo Gómez-Fernández |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-05-01
|
Series: | Nefrología (English Edition) |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2013251421000675 |
Similar Items
-
Bloqueantes del receptor mineralcorticoide en la enfermedad renal crónica
by: Sara Erraez, et al.
Published: (2021-05-01) -
Características clínicas de los pacientes diabéticos que acuden por primera vez a una consulta nefrológica en hospitales públicos de Lima
by: Percy Herrera Añazco, et al.
Published: (2014-01-01) -
The Efficacy of the Mineralcorticoid Receptor Antagonist Canrenone in COVID-19 Patients
by: Marco Vicenzi, et al.
Published: (2020-09-01) -
Bloqueo del sistema renina-angiotensina-aldosterona en pacientes con enfermedad renal diabética avanzada
by: Sheila Bermejo, et al.
Published: (2018-03-01) -
Educational intervention on chronic renal failure in patients with type-2 diabetes mellitus
by: Onelis Góngora Gómez, et al.
Published: (2019-04-01)